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The Rho/ROCK pathway is a promising therapeutic target in neurodegenerative and
neurotraumatic diseases. Pharmacological inhibition of various pathway members
has been shown to promote neuronal regeneration and survival. However, because
pharmacological inhibitors are inherently limited in their specificity, shRNA-mediated
approaches can add more information on the function of each single kinase involved.
Thus, we generated adeno-associated viral vectors (AAV) to specifically downregulate
Ras homologous member A (RhoA) via shRNA. We found that specific knockdown
of RhoA promoted neurite outgrowth of retinal ganglion cells (RGC) grown on the
inhibitory substrate chondroitin sulfate proteoglycan (CSPG) as well as neurite regeneration
of primary midbrain neurons (PMN) after scratch lesion. In the rat optic nerve crush
(ONC) model in vivo, downregulation of RhoA significantly enhanced axonal regeneration
compared to control. Moreover, survival of RGC transduced with AAV expressing
RhoA-shRNA was substantially increased at 2 weeks after optic nerve axotomy. Compared
to previous data using pharmacological inhibitors to target RhoA, its upstream regulator
Nogo or its main downstream target ROCK, the specific effects of RhoA downregulation
shown here were most pronounced in regard to promoting RGC survival but neurite
outgrowth and axonal regeneration were also increased significantly. Taken together, we
show here that specific knockdown of RhoA substantially increases neuronal survival
after optic nerve axotomy and modestly increases neurite outgrowth in vitro and axonal
regeneration after optic nerve crush.
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INTRODUCTION
Neuronal cell death, axonal degeneration and regenerative failure
are the central pathological hallmarks of most traumatic and
neurodegenerative diseases of the central nervous system (CNS).
As these pathomechanisms usually occur concurrently and influ-
ence each other, therapeutic approaches should optimally address
molecular targets that act on all of these processes. Based on
growing evidence, the Rho/ROCK/LIMK-pathway appears to be
an excellent candidate to fulfill these criteria (Mueller et al., 2005;
Tönges et al., 2011a). However, it is not clear which pathway
members are most suitable to be targeted to address specific
pathological mechanisms.
Abbreviations: AAV, adeno-associated viral vector; ANOVA, analysis of vari-
ance; BSA, bovine serum albumin; CNS, central nervous system; CSPG,
chondroitin sulfate proteoglycan; DAPI, 4,6-diamidino-2-phenylindole; DIV,
day in vitro; GAP43, growth associated protein 43; LIMK, LIM domain kinase;
PMN, primary midbrain neurons; ONC, optic nerve crush; PBS, phosphate-
buffered saline; PFA, paraformaldehyde; RGC, retinal ganglion cells; RhoA,
Ras homologous member A; ROCK, Rho-associated protein kinase; RT-PCR,
real-time polymerase chain reaction; siRNA, small interfering RNA; shRNA,
small hairpin RNA; TU, transforming units.
The Rho/ROCK/LIMK-pathway is activated by several extra-
cellular growth-inhibitory signals, including Nogo, ephrins
(Shamah et al., 2001) and semaphorins (Dontchev and
Letourneau, 2003; Lin et al., 2007). Their signaling is medi-
ated through different transmembrane receptors, e.g., the ephrin
receptor and the trimeric NogoR/p75/Lingo1 receptor complex.
These receptors lead to an activation of Ras homologous member
A (RhoA; Wahl et al., 2000), which finally results in growth
cone collapse and retraction of neurites (Jalink et al., 1994;
Mackay et al., 1995; Tigyi et al., 1996; Katoh et al., 1998; Gu
et al., 2013). One of the best-characterized downstream targets
of RhoA is the Rho-associated coiled-coil-containing protein
kinase (ROCK) that is activated by RhoA (Ishizaki et al., 1997).
ROCK itself has several downstream targets that affect both
neuronal survival and actin cytoskeleton, including phosphatase
and tensin homolog (PTEN), myosin light chain kinase and
LIM domain kinase (LIMK; Endo et al., 2003; Tönges et al.,
2011a). LIMK phosphorylates and thereby inactivates the actin-
depolymerizing factor cofilin which leads to decreased actin
turnover and growth cone collapse (Arber et al., 1998). Next
to its functions in developmental axon guidance (Luo, 2000),
the Rho/ROCK/LIMK-cascade also plays an important role after
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traumatic lesions of the CNS when it mediates inhibition of
axonal regeneration (Moreau-Fauvarque et al., 2003; Mueller
et al., 2005). Another downstream target of RhoA is mammalian
diaphanous (mDia) which acts on actin and tubulin polymeriza-
tion independently of ROCK (Watanabe et al., 1997; Luo, 2000).
The involvement of RhoA in retinal ganglion cell (RGC)
pathology has been demonstrated previously. Expression lev-
els of RhoA increased significantly in the retina within 7 days
after rat optic nerve crush (ONC; Wang et al., 2007) and in
the RGC-layer within 8 days after rat optic nerve infarction
(Fard et al., 2013). In human glaucoma patients, increased
RhoA-protein-levels were observed in the optic nerve head
compared to healthy age-matched controls (Goldhagen et al.,
2012).
Several groups have assessed the effects of Rho-inhibition
in vitro and in different animal models (Donovan et al., 1997;
Mills et al., 1998; Lehmann et al., 1999; Monnier et al., 2003;
Fischer et al., 2004; Zhang et al., 2007; Julien et al., 2008), mostly
with positive effects regarding neurite outgrowth and axonal
regeneration. To inhibit Rho, all of these studies have used the
C3 enzyme from Clostridium botulinum that inactivates Rho by
ADP-ribosylation (Rubin et al., 1988; Udagawa and McIntyre,
1996). However, C3 is not specific for RhoA, but also modifies the
Rho isoforms RhoB and RhoC (Just et al., 2011). Moreover, C3
was shown to activate microglia and trigger the release of nitric
oxide and several proinflammatory cyto- and chemokines inde-
pendently of RhoA/ROCK-activation (Hoffmann et al., 2008). It
also acts on astrocytes inducing glial scar formation (Just et al.,
2011).
In the present study, we use short hairpin RNA (shRNA)
against RhoA expressed by adeno-associated viral vectors (AAV)
to specifically analyze the effects of RhoA downregulation in
models of neuronal de- and regeneration in vitro and in vivo.
Extending our recently published work on the effects of specific
downregulation of ROCK2 and LIMK1 (Koch et al., 2014), we
provide important evidence on the functions and therapeutic
potential of RhoA, one of their upstream regulators.
MATERIAL AND METHODS
CLONING, PRODUCTION AND TESTING OF AAV
Adeno-associated viral vectors were produced based on the
previously published vectors pAAV-9(5)hSyn-DsRed-H1-EGFP-
shRNA (= pAAV-Si-I (GenBank ID: AY6406334, Michel et al.,
2005)) and pAAV-9(5)hSyn-DsRed-H1-RhoA-shRNA3 (Malik
et al., 2006). The shRNA sense sequence was AAGCTGAC-
CCTGAAGTTCA for the EGFP-shRNA and CTATGTGGCA-
GATATTGAA GT for the RhoA-shRNA.
AAV were produced as reported before (Koch et al., 2011a).
Briefly, 293-HEK cells were transfected with the specific plasmid
mix (for AAV2: pAAV expression vector, pAAV-RC and pHELPER
(both from Stratagene, Amsterdam, Netherlands) in a 1:1:1 molar
ratio; for AAV2/1: pAAV expression vector, pHELPER, pAAV-RC
and pH21 in a 1:1:0.5:0.5 molar ratio) under addition of cal-
cium phosphate and HEPES buffered saline. Cells were harvested
48 h after transfection, and AAV were purified by dialysis and
virus gradient centrifugation in iodixanol. To obtain high titer
viral stocks, we performed fast protein liquid chromatography
(FPLC). Virus stocks were tested on primary cortical neurons for
transduction efficacy and toxicity and viral titers were determined
using qPCR. Based on previous comparisons of different AAV-
serotypes (Koch et al., 2013), we used the serotype AAV2/1 for
all in vitro experiments whereas all in vivo experiments were
performed with AAV2.
Efficacy of RhoA downregulation was assessed in rat pri-
mary hippocampal cell culture that was prepared as described
elsewhere (Audesirk et al., 2001). Neurons were transduced on
day in vitro (DIV) 1 with AAV in a concentration of 1 × 108
transforming units (TU) per well. On DIV 7, cells were lysed in
ice-cold lysis buffer (10 mM Hepes, 142 mM KCl, 5 mM MgCl,
2.1 mM EGTA, IGEPAL, protease and phosphatase inhibitor
and dithiothreitol). Cell lysates were sonicated, resolved on
SDS-PAGE and blotted on a nitrocellulose membrane. For fur-
ther standard Western Blot processing, the following antibodies
were used: rabbit polyclonal anti-dsRed (Clontech, Heidelberg,
Germany), mouse monoclonal anti-RhoA (26C4) (sc-418, Santa
Cruz, Heidelberg, Germany) and mouse monoclonal anti-β-
tubulin (Sigma, St. Louis, MO, USA). As secondary antibodies,
we used horseradish peroxidase-conjugated goat anti-rabbit and
anti-mouse antibodies (Santa Cruz). Bands were visualized using
enhanced chemiluminescence (ECL-solution: 250 mM Luminol,
90 mM p-coumaric acid, 1 M Tris / HCl, 30% hydrogen perox-
ide) and quantified with ImageJ software1 (open freeware pro-
vided by the NIH, Bethesda, MD, USA) (3 independent protein
lysates).
PRIMARY RETINAL GANGLION CELLS (RGC) AND EVALUATION OF
NEURITE OUTGROWTH
Retinal ganglion cells were prepared from 7 days old Wistar
rat pups as described before (Koch et al., 2011a). Retinal gan-
glion cells were enriched to 99.5% purity using a two-step pan-
ning protocol for Thy-1 (Barres et al., 1988). Cells were plated
in 24-well-plates in a density of 4000 cells per well in RGC
medium composed of serum-free neurobasal medium (Gibco,
Life Technologies, Darmstadt, Germany) supplemented with
sodium-pyruvate (Sigma-Aldrich, Seelze, Germany), glutamine,
N-acetyl-cysteine, triiodothyronine, Sato (BSA, transferrin, pro-
gesterone, putrescine, sodium selenite; Gibco), forskolin (final
concentration 10 mM), human BDNF (final concentration
50 ng/ml; Tebu, Offenbach, Germany), insulin (final concen-
tration 5 mg/ml; Sigma-Aldrich), CNTF (final concentration
10 ng/ml; Tebu) and B27 supplement. Coverslips (Sarstedt,
Nümbrecht, Germany) were coated with poly-D-lysine (Sigma-
Aldrich) and either laminin (20 µg/ml; Sigma-Aldrich) or
chondroitin sulfate proteoglycan (CSPG; 50 µg/ml; major com-
ponents: neurocan, aggrecan, phosphacan and versican; Chemi-
con; Darmstadt, Germany).
For viral transduction, the medium was reduced to 250 µl per
well at 4 h after seeding and AAV were added in a concentration
of 5 × 107 TU per well. After 24 h, 250 µl fresh medium were
added to each well. Transduction efficacy of RGCs (>90% after
DIV 3) and possible virus toxicity (<10% cell death until DIV 5)
were monitored regularly.
1http://imagej.nih.gov/ij/
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To assess neurite outgrowth, micrographs of four randomly
chosen visual fields per well of five wells per group were taken on
DIV 5 with an inverted microscope (Axiovert, Zeiss, Göttingen,
Germany). On the micrographs, the total neurite length per
view field was quantified using the neurite tracing module of
the ImageJ plugin NeuronJ (Meijering et al., 2004) and then
divided by the number of neurons per view field to obtain the
mean neurite length per RGC. Results from two independent
experiments were statistically evaluated using one-way ANOVA
followed by Dunnett’s post hoc test with significance at p< 0.05.
PRIMARY MIDBRAIN NEURONS (PMN) AND SCRATCH ASSAY
Primary midbrain neurons were prepared from embryonic
day 14 Wistar rats as described previously (Lingor
et al., 1999). Cells were seeded in a density of 4 × 105
neurons/cm2 on poly-L-ornithine/laminin-coated cover slips
in PMN-medium (composed of DMEM F12, glucose, BSA,
penicillin/streptomycin/neomycin, N1, glutamin and insulin;
all Sigma). Four hours after seeding, AAV were added in a
concentration of 0.5× 108 TU per well. On DIV 3, a scratch assay
was performed as described before (Tönges et al., 2011b). In brief,
a custom-made 2 mm broad silicon rubber scratch device was
scratched once across each coverslip. Successful transection of all
neurites along the scratch border was verified under a microscope.
Following the scratch lesion, half of the medium was exchanged.
On DIV 6, the cells were fixed in 4% PFA and a standard
immunocytochemistry against tyrosine hydroxylase (TH) was
performed (primary antibody: rabbit anti-TH (AB152; Millipore,
Darmstadt, Germany); secondary antibody: cy3-labelled mouse
anti-rabbit (Dianova, Hamburg, Germany)). Micrographs were
taken along both scratch borders with a 20× objective using an
Axioplan microscope equipped with a 16-bit grayscale CCD cam-
era and AxioVision 4.6 software (Zeiss). On each micrograph, the
lengths of the 10 longest neurites growing across the scratch bor-
der were determined using the ImageJ plugin NeuronJ. Per group,
10 micrographs were evaluated. Experiments were repeated
in three independent PMN-cultures. Results were statistically
evaluated using Student’s t-test with significance at p< 0.05.
ANIMAL EXPERIMENTS
All animal experiments were performed according to the reg-
ulations of the local animal research council and legislation
of the State of Lower Saxony, Germany. Adult female Wistar
rats (200–300 g, Charles River, Sulzfeld, Germany) were used
for all animal experiments. All surgical procedures (intravitreal
virus injection, optic nerve crush, stereotactical injection, axo-
tomy) were performed under deep anesthesia with 10% ketamine
(95 mg/kg body weight) and 2% xylazine (7 mg/kg body weight)
injected intraperitoneally.
INTRAVITREAL VIRUS INJECTION, OPTIC NERVE CRUSH AND GAP43
IMMUNOHISTOCHEMISTRY
AAV.EGFP-shRNA or AAV.RhoA-shRNA (1 × 109 TU in 5 µl)
were injected intravitreally with a Hamilton syringe as described
before (Koch et al., 2011b). An ONC was performed 3 weeks after
intravitreal injections as described previously (Koch et al., 2011b).
In brief, the orbita was accessed after incision along the orbital
rim. After moving the lacrimal gland to the front, the eye bulb was
slightly rotated to the side by pulling the superior rectus muscle.
Then, the optic nerve was fully exposed by removing the sur-
rounding tissue. A 10-0 polyamide suture (Ethicon, Somerville,
NJ, USA) was constricted around the optic nerve for 30 s at a
distance of 1.5 mm from its insertion into the eye bulb. Next,
the suture was removed and all tissue put back in situ. Twenty
eight days after ONC, animals were perfused transcardially with
4% PFA and the optic nerve and eye bulb were resected and post-
fixed in 4% PFA for 1 h. The retina was flat-mounted in 30%
glycerol to assess viral transduction efficacy, which was 20–50% of
all RGC. Three animals were excluded from further analysis due to
transduction rates <20%. The optic nerves were cryo-protected
in 30% sucrose for 48 h and then cryo-sectioned longitudinally
(thickness: 16 µm). Cryosections were stained with standard
immunohistochemistry methods against GAP43 (monoclonal
antibody, Abcam). Cy2-labeled secondary antibodies (Dianova)
were used and sections were counter-stained with DAPI (Sigma)
and mounted in Moviol (Hoechst). All optic nerve sections were
photographed with an Axioplan microscope equipped with Axio-
Vision Software (Zeiss). The number of GAP43 positive axons
was counted at defined distances from the crush site. The crush
site could be clearly localized due to scar formation and high cell
density in the DAPI-stain. For statistical analysis, the numbers
of axons at a given distance from the crush site were compared
between both groups using the Wilcoxon (Mann-White) test for
unpaired data with significance at p< 0.05.
AXOTOMY OF THE OPTIC NERVE
For axotomy experiments, AAV were injected intravitreally as
described above. Three weeks later, the optic nerve was exposed
as described above for the ONC and then transsected at 2 mm
from the posterior eye pole taking special care not to damage the
retinal blood supply. To retrogradely label the RGCs, a 2 mm × 2
mm piece of gel foam (Braun, Melsungen, Germany) was soaked
in FluoroGold®(Hydroxystilbamidine; Bio-Trend, Cologne, Ger-
many) and placed on the optic nerve stump. At 14 days after
axotomy, the animals were perfused and the retinas flat-mounted
as described above. Further examinations were performed under
an Axioplan microscope (Zeiss). Using 2.5× and 10× magni-
fications, the retina was subdivided into transduced and non-
transduced areas. For each area-type, four 40× magnification
view fields were evaluated at similar distances from the optic
disc. Fluorogold®-labeled RGC were counted using a UV filter
(365/420 nm). RGC were discriminated from other Fluorogold-
positive cells (microglia, macrophages etc.) by morphological
criteria (soma size, form of processes). For EGFP-shRNA n = 7
animals were evaluated, for RhoA-shRNA n= 8 animals were eval-
uated. Data were evaluated statistically using Wilcoxon (Mann-
White) test for unpaired data with significance at p< 0.05.
RESULTS
DOWNREGULATION OF RhoA
Based on previous testing (Malik et al., 2006), we chose the
most potent and specific AAV.shRNA to downregulate RhoA
under the control of the H1 promoter and co-expressing the
fluorophore dsRed under the control of the human synapsin
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FIGURE 1 | AAV.shRNA-mediated downregulation of RhoA. (A) Vector
maps of AAV.RhoA-shRNA and the control-vector AAV.EGFP-shRNA. The
shRNAs are expressed under the control of an H1 promoter and the
fluorophore dsRed is expressed under the control of a human
synapsin-1 promoter. ITR: AAV-2 inverted terminal repeat. Int: intron.
SV40-pA: SV40 polyadenylation site. (B) Immunoblots for RhoA and
dsRed of primary hippocampal neurons transduced with
AAV.RhoA-shRNA or AAV.EGFP-shRNA (n = 3 independent protein
lysates per group; bars represent means ± SEM: * p < 0.05 according
to Student’s t-test).
promoter. As control, we employed the same vector express-
ing an shRNA against EGFP (Koch et al., 2011a, 2014) (vec-
tor maps are shown in Figure 1A). Specific downregulation
of the target protein RhoA was confirmed by immunoblot of
protein lysates from AAV-transduced primary hippocampal neu-
ron cultures. Transduction with AAV.RhoA-shRNA resulted in
a significant downregulation of RhoA expression levels to 35
± 0.18% compared to AAV.EGFP-shRNA which was set 100%
(Figure 1B).
INHIBITION OF NEURITE OUTGROWTH BY CSPG IS COUNTERACTED BY
DOWNREGULATION OF RhoA
RhoA has been reported to be a key intracellular mediator of
repulsive signaling from surrounding glia cells on the growing
axon (Luo, 2000). To simulate the inhibitory environment present
in the adult mammalian CNS, we cultured rat primary RGC
on the growth-inhibiting substrate CSPG, which contains some
of the key inhibiting molecules produced by glial cells of the
CNS in vivo (Niederöst et al., 1999). As control, RGC were
cultured on the growth permissive coating laminin. On DIV 5,
the mean neurite length per neuron was measured for RGC on
both coatings with or without viral transduction. There was no
significant difference between the untreated RGC (mean neu-
rite length per cell: 1761 ± 92 µm) and RGC transduced with
AAV.EGFP-shRNA (1998 ± 101 µm) on laminin. In contrast to
RGC cultured on laminin, neurite growth on CSPG-coating was
significantly reduced in untreated RGC (mean neurite length 604
± 56 µm) and RGC transduced with AAV.EGFP-shRNA (689
± 120 µm). This inhibition of neurite outgrowth was partly
rescued by transduction with AAV.RhoA-shRNA, which led to
a significantly increased mean neurite length (1240 ± 85 µm)
compared to AAV.EGFP-shRNA-treated controls (Figure 2).
NEURITE REGENERATION AFTER SCRATCH LESION IS IMPROVED BY
RhoA-shRNA
Neurites in the CNS exhibit an insufficient regeneration capac-
ity after traumatic or biochemical lesion, e.g., by oxidative
stress, which has relevance for the pathogenesis of numerous
neurological disorders. To mimic this situation, we performed a
scratch assay in rat PMN (Tönges et al., 2011b). Primary midbrain
neurons were transduced with AAV.EGFP-shRNA or AAV.RhoA-
shRNA and on DIV 3 a mechanical neurite transection was
performed using a special rubber device that was scratched across
the cover slip 3 days later, cells were fixed and stained against TH
to identify dopaminergic neurons. Micrographs were taken along
the scratch border and the length of the 10 longest TH-positive
neurites growing across the scratch border was assessed. The mean
length of these regenerating neurites was significantly increased
in the neurons transduced with RhoA-shRNA (538 ± 16 µm) as
compared to EGFP-shRNA (387 ± 14 µm; Figure 3).
DOWNREGULATION OF RhoA PROMOTES AXONAL REGENERATION
AFTER OPTIC NERVE CRUSH
Next, we analyzed the effects of RhoA downregulation on axonal
regeneration in vivo. AAV.EGFP-shRNA or AAV.RhoA-shRNA
were injected intravitreally in adult female Wistar rats. Three
weeks after intravitreal injection, a crush lesion of the optic
nerve (ONC) was performed as described before (Koch et al.,
2011b). The animals were sacrificed 3 weeks later and the optic
nerves were immunostained with an antibody against GAP43 to
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FIGURE 2 | Downregulation of RhoA partly rescues the inhibitory
effects of CSPG on neurite outgrowth in RGC. (A) Representative
micrographs of RGC on DIV 5 without AAV-treatment (untreated) or
transduced with AAV.EGFP-shRNA or AAV.RhoA-shRNA (AAV-expressed
dsRed). Neurites of the RGC without treatment or transduced with
AAV.EGFP-shRNA are clearly shorter on the non-permissive substrate
CSPG (on the right side) as compared to laminin (on the left side). In
contrast, RGC transduced with AAV.RhoA-shRNA grow long neurites on
CSPG. (B) Quantification of the mean neurite length per RGC
transduced with the given AAV or untreated and plated either on laminin
or CSPG (n = 2 RGC-cultures; quantification of 20 fields of view per
group and experiment; bars represent means ± SEM; ** p < 0.005,
*** p < 0.001, according to one-way ANOVA followed by Dunnett’s
post hoc test).
specifically identify regenerating axons (Schaden et al., 1994). The
number of GAP43-positive axons was quantified at increasing
distances from the crush site (Figures 4A,B). Transduction with
AAV.RhoA-shRNA resulted in a significant increase of regenerat-
ing axons that had crossed the lesion site compared to AAV.EGFP-
shRNA (n = 10 optic nerves per group). This effect was, however,
limited to the area close to the crush as no regenerating axons
could be observed at distances >600 µm from the crush site in
neither group. The number of GAP43-positive axons at 100 µm
proximal to the crush site was also increased significantly in the
optic nerves transduced with AAV.RhoA-shRNA as compared to
AAV.EGFP-shRNA, indicating increased stability of RGC axons
following crush lesion (mean number of GAP43-positive neu-
rites per section: EGFP-shRNA: 19 ± 3; RhoA-shRNA: 38 ± 4;
Figure 4C).
RGC SURVIVAL AFTER OPTIC NERVE AXOTOMY IS IMPROVED BY
DOWNREGULATION OF RhoA
To test possible pro-survival effects of RhoA-downregulation
in vivo, we employed the optic nerve axotomy model in adult
female Wistar rats. AAV.EGFP-shRNA or AAV.RhoA-shRNA were
injected intravitreally. Three weeks later, a complete axotomy of
the optic nerve was performed and RG were labeled by application
of FluoroGold® to the optic nerve stump. After another 2 weeks,
the number of FluoroGold®-labeled RGC was quantified on reti-
nal flat-mounts (Figure 5). Viral transduction rates were similar
for both groups: transduced (dsRed-positive) RGC in percent of
all (FluoroGold®-positive) RGC: AAV.EGFP-shRNA: 45%, RhoA-
shRNA 53% (p = 0.534, Student’s t-test). To specifically assess
effects of the AAV-treatment and to avoid a possible bias caused
by differences of RGC numbers between animals and different
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 273 | 5
Koch et al. RhoA-shRNA improves survival and regeneration
FIGURE 3 | Rho-shRNA enhances neurite regeneration after mechanical
scratch lesion. (A) Representative micrographs of primary midbrain neurons
(PMN) transduced with AAV expressing the respective shRNA given on top
and immunostained against tyrosine hydroxylase (TH). Photos were taken on
DIV 6, 72 h after mechanical scratch lesion. The scratch border is shown at
the bottom on each picture with neurites growing across the scratch.
(B) Quantification showing the mean lengths of the 10 longest TH-positive
neurites crossing the scratch border after transduction with AAV expressing
the shRNAs given below. Data are given as means ± SEM. ** P < 0.005
according to Student’s t-test; (n = 3 independent PMN-cultures; quantification
of 10 × 10 neurites per group per culture, i.e., in total 300 neurites per
condition).
regions of the retina, we defined four regions per retina that were
not transduced by the AAV and directly compared the respective
RGC-numbers of these regions with four AAV-transduced regions
of the same retina in a similar distance from the optic disc
(Figure 5A). Transduction with AAV.RhoA-shRNA resulted in a
significantly increased number of RGC (149 ± 27%) compared
to AAV.EGFP-shRNA (104 ± 3%; p = 0.012, Student’s t-test;
Figure 5C).
DISCUSSION
Accumulating evidence suggests that modulation of the
Rho/ROCK/LIMK pathway has favorable therapeutic effects
in several neurological diseases (Mueller et al., 2005; Tönges et al.,
2011a, 2012; Koch et al., 2014). In the present study we analyzed
the therapeutic value of the specific knockdown of RhoA in
CNS neurons with regards to axonal regeneration and neuronal
survival.
We demonstrate that knockdown of RhoA partly rescues
CSPG-induced inhibition of neurite outgrowth in RGC in vitro,
increases neurite regeneration of dopaminergic neurons
after scratch lesion in vitro and moderately enhances axonal
regeneration after ONC in vivo. These results extend previous
studies employing C3-enzyme in RGC or RhoA-siRNA in other
neuronal cells.
In PC12 cells on a permissive substrate, RhoA-shRNA
decreased F-actin levels and increased the percentage of neurite-
bearing cells, but changes in neurite lengths were not assessed
(Fan et al., 2008). RhoA-siRNA abolished semaphorin-3A-
induced growth cone collapse in rat dorsal root ganglion cell
cultures (Hengst et al., 2006), but no other inhibitory factors
were tested in this study. In RGC in vitro, Rho-inhibition by C3-
enzyme completely rescued inhibition of neurite growth induced
by CSPG (Monnier et al., 2003) or myelin-substrates (Lehmann
et al., 1999). In contrast to these reported effects of C3-treatment,
the Rho-shRNA in our study only partly rescued the growth-
inhibiting effects of CSPG. This might be due to the fact that the
downregulation reduced intraneuronal RhoA levels only by 65%
compared to normal levels resulting in a significantly reduced but
possibly still functionally relevant RhoA-activity. Additionally, C3
unspecifically inhibits all Rho-isoforms including RhoA, RhoB
and RhoC (Just et al., 2011) in contrast to the target-specific
RhoA-shRNA. As RhoB was also shown to modulate actin and
tubulin dynamics in neurons (Mackay et al., 1995), it is possible
that the other Rho-isoforms mediate growth-inhibiting effects
when specifically RhoA is downregulated. In favor of the latter
explanation, we recently found that a similar knockdown efficacy
(60–70%) of ROCK2 and LIMK1 was sufficient to completely
rescue CSPG-induced neurite growth inhibition in RGC (Koch
et al., 2014).
It has to be noted that the in vitro tests for neurite regeneration
after scratch lesion were performed in PMN. Due to the low
number of neurons in the RGC-cultures it would have been
very difficult to induce a reproducible lesion of the neurites in
RGC and to statistically evaluate the effects of RhoA-shRNA. The
scratch lesion in PMN on the other hand, is a well-established
experimental paradigm (Tönges et al., 2011b). Although it repre-
sents a different neuronal cell type, it nicely demonstrates in vitro
the therapeutic capacity of RhoA-downregulation for neurite
regeneration after a traumatic lesion, extending the findings on
neurite outgrowth in RGC to another pathological condition
and another neuronal cell type. Moreover, these results imply
positive effects of RhoA-shRNA in dopaminergic neurons, thus
setting the stage for further experiments in models of Parkinson’s
disease.
In the ONC model in vivo, the pro-regenerative effects of
C3-enzyme applied locally in gelfoam (Lehmann et al., 1999) or
expressed by intravitreally injected AAV (Fischer et al., 2004) have
been examined previously. Both studies reported moderate pro-
regenerative effects of the C3-treatment with increased axonal
regeneration up to 500 µm distal to the crush lesion, compara-
ble to our present results. A significantly stronger regenerative
response could be induced by concurrent C3-treatment and lens
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FIGURE 4 | Knockdown of RhoA increases axonal regeneration after
optic nerve crush. (A) Representative composite photos of optic nerves
transduced with AAV.EGFP-shRNA or AAV.RhoA-shRNA and immunostained
for GAP43. AAV were injected intravitreally 14 days before crush lesion.
Optic nerve sections were obtained 28 days after crush. White arrow-heads
point at regenerating (GAP43-positive) axons. (B) Quantification of the
number of GAP43-positive axons at different distances from the crush site
(n = 10 optic nerves per group; bars represent means ± SEM; * p < 0.05;
** p < 0.005 according to Student’s t-test). (C) Quantification of the
number of GAP43-positive axons at 100 µm proximal to the crush site
shows a significant increase only for the optic nerves transduced with
AAV.RhoA-shRNA (n = 10 optic nerves per group; bars represent means ±
SEM; * p < 0.05, according to Wilcoxon (Mann-White) test for unpaired
data).
injury (Fischer et al., 2004) or by single knockdown of the RhoA
downstream targets ROCK2 and LIMK1 (Koch et al., 2014). The
most effective therapeutic approaches to foster axonal regenera-
tion in the optic nerve published so far address the PTEN and
mTOR pathway (de Lima et al., 2012). Interestingly, there is a
putative molecular link between the RhoA-downstream target
ROCK2 and PTEN (Tönges et al., 2011a). Comparing the amount
and length of regenerating axons of our present study to these
previous results, the effects of specific RhoA-downregulation are
clearly less pronounced than PTEN and mTOR modulation or
C3-treatment and additional lens injury. In line with our results
in the optic nerve, RhoA-siRNA applied by intraspinal injections
or lumbar puncture had only minor positive effects on motorical
outcome in a rat spinal cord injury model although improved
sensory function and white matter preservation were reported
(Otsuka et al., 2011).
We conclude that the neurite-growth-inhibiting signals in vivo
employ additional other pathways next to RhoA and that targeting
RhoA alone is not sufficient to promote a substantial regenerative
response after axonal lesions in the CNS in vivo, especially taking
into account the more promising previous results employing
specific ROCK2- or PTEN-inhibition.
We further report here, that RhoA-shRNA significantly
increased survival of RGC after optic nerve axotomy. Several
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FIGURE 5 | RhoA-shRNA increases RGC survival after optic nerve
axotomy. (A) Composite figure explaining the evaluation method used to
assess RGC-survival after optic nerve axotomy. Retina flat mounts were
obtained 14 days after transection of the optic nerve. Per retina, four view
fields were evaluated in a region that was not transduced by the AAV
(dashed circles in the left micrograph) and directly compared to four view
fields in an AAV-transduced region (dashed circles on the right micrograph)
of the same retina in a similar distance from the optic disc.
(B) Representative micrographs of transduced view fields from retina flat
mounts transduced with the given AAV in red and Fluorogold positive cells
in blue. (C) Quantification of the number of Fluorogold-positive RGC given
in percent of AAV.EGFP-shRNA control (set to 100%) (n = 7 retinas for
AAV.EGFP-shRNA and n = 8 retinas for AAV.RhoA-shRNA; bars represent
means ± SEM; * p < 0.05 according to Wilcoxon (Mann-White) test for
unpaired data).
in vitro studies in different neuronal cells support the notion
that an activation of RhoA results in increased cell death while
an inhibition of RhoA has anti-apoptotic effects: Rho-inhibition
with C3-enzyme attenuated thrombin-induced cell death in hip-
pocampal neurons (Donovan et al., 1997), inhibited apoptotic
membrane blebbing in PC12 cells (Mills et al., 1998), increased
survival of organotypic Purkinje cells (Julien et al., 2008) and
rescued cortical neurons from phenylalanine-induced apoptosis
(Zhang et al., 2007), while overexpression of RhoA caused high
levels of apoptosis in cortical neurons during early postnatal
development (Sanno et al., 2010). Moreover, it was shown that
RhoA is essential for glutamate-induced cell death of cerebel-
lar granule neurons, being activated by elevated intracellular
calcium levels and acting via p38α (Semenova et al., 2007).
In Drosophila melanogaster, the RhoA-homolog Rho1 promoted
apoptosis independently of ROCK through its effects on c-Jun
NH2-terminal kinase (JNK) signaling (Neisch et al., 2010). On
the other hand, a few studies reported negative effects of Rho-
inhibition on neuronal survival: C3-enzyme induced apoptosis in
different neuroglioma cell lines (Udagawa and McIntyre, 1996)
and expression of dominant negative RhoA increased apoptosis
of spinal cord motor neurons during embryonal development
(Kobayashi et al., 2004). In disease models in vivo, there is,
to the best of our knowledge, no evidence for the effects of
specific RhoA-downregulation on neuronal survival. However,
in line with our results, Rho-inhibition with C3-enzyme in the
ONC model resulted in an increased RGC-number (Fischer et al.,
2004).
Our present data identify the isoform RhoA to be involved in
neuronal cell death after optic nerve axotomy in vivo. The amount
of the pro-survival effect was similar to the effects previously
observed for ROCK2-shRNA in the same model system (Koch
et al., 2014), suggesting that ROCK2 is the main molecular medi-
ator of the anti-apoptotic effects of RhoA. Due to the limitations
of the shRNA-approach discussed above, it is, however, also
possible that other known downstream targets of RhoA with anti-
apoptotic effects, e.g., JNK or p38 α, are involved. This could
strengthen the therapeutic value of RhoA-inhibition compared to
ROCK-inhibition with regards to neuronal survival.
Taken together, we show here that knockdown of RhoA
resulted in a modest increase of neurite outgrowth of RGC and
PMN in vitro and of axonal regeneration after ONC in vivo
while RGC survival after optic nerve axotomy was substantially
increased. These findings thus characterize in more detail the
specific functions of RhoA with importance to pathobiology of
traumatic and degenerative CNS disorders and contribute to
an improved understanding of the value of RhoA as a putative
therapeutic target.
ACKNOWLEDGMENTS
The authors want to thank Elisabeth Barski for excellent technical
support. Jan Christoph Koch and Paul Lingor were supported by
a grant of the Deutsche Forschungsgemeinschaft (LI 1308/3-1).
Mathias Bähr and Paul Lingor were supported by the Cluster of
Excellence and DFG Research Center Nanoscale Microscopy and
Molecular Physiology of the Brain (CNMPB), Göttingen. We are
indebted to the “Open-Access-Publikationsfonds der DFG” for
contribution to the publication costs.
REFERENCES
Arber, S., Barbayannis, F. A., Hanser, H., Schneider, C., Stanyon, C. A., Bernard, O.,
et al. (1998). Regulation of actin dynamics through phosphorylation of cofilin
by LIM-kinase. Nature 393, 805–809. doi: 10.1038/31729
Audesirk, G., Audesirk, T., and Ferguson, C. (2001). Culturing rat hippocampal
neurons. Curr. Protoc. Toxicol. Chapter 12, Unit12.13. doi: 10.1002/0471140856.
tx1203s04
Barres, B. A., Silverstein, B. E., Corey, D. P., and Chun, L. L. (1988). Immunological,
morphological and electrophysiological variation among retinal ganglion cells
purified by panning. Neuron 1, 791–803. doi: 10.1016/0896-6273(88)90127-4
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 273 | 8
Koch et al. RhoA-shRNA improves survival and regeneration
de Lima, S., Koriyama, Y., Kurimoto, T., Oliveira, J. T., Yin, Y., Li, Y., et al.
(2012). Full-length axon regeneration in the adult mouse optic nerve and partial
recovery of simple visual behaviors. Proc. Natl. Acad. Sci. U S A 109, 9149–9154.
doi: 10.1073/pnas.1119449109
Donovan, F. M., Pike, C. J., Cotman, C. W., and Cunningham, D. D. (1997).
Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway
requiring tyrosine kinase and RhoA activities. J. Neurosci. 17, 5316–5326.
Dontchev, V. D., and Letourneau, P. C. (2003). Growth cones integrate signaling
from multiple guidance cues. J. Histochem. Cytochem. 51, 435–444. doi: 10.
1177/002215540305100405
Endo, M., Ohashi, K., Sasaki, Y., Goshima, Y., Niwa, R., Uemura, T., et al. (2003).
Control of growth cone motility and morphology by LIM kinase and Slingshot
via phosphorylation and dephosphorylation of cofilin. J. Neurosci. 23, 2527–
2537.
Fan, Y. M., Pang, C. P., Harvey, A. R., and Cui, Q. (2008). Marked effect of RhoA-
specific shRNA-producing plasmids on neurite growth in PC12 cells. Neurosci.
Lett. 440, 170–175. doi: 10.1016/j.neulet.2008.05.045
Fard, M. A., Ebrahimi, K. B., and Miller, N. R. (2013). RhoA activity and post-
ischemic inflammation in an experimental model of adult rodent anterior
ischemic optic neuropathy. Brain Res. 1534, 76–86. doi: 10.1016/j.brainres.2013.
07.053
Fischer, D., Petkova, V., Thanos, S., and Benowitz, L. I. (2004). Switching mature
retinal ganglion cells to a robust growth state in vivo: gene expression and syn-
ergy with RhoA inactivation. J. Neurosci. 24, 8726–8740. doi: 10.1523/jneurosci.
2774-04.2004
Goldhagen, B., Proia, A. D., Epstein, D. L., and Rao, P. V. (2012). Elevated levels of
RhoA in the optic nerve head of human eyes with glaucoma. J. Glaucoma 21,
530–538. doi: 10.1097/ijg.0b013e318241b83c
Gu, H., Yu, S. P., Gutekunst, C. A., Gross, R. E., and Wei, L. (2013). Inhibition of the
Rho signaling pathway improves neurite outgrowth and neuronal differentiation
of mouse neural stem cells. Int. J. Physiol. Pathophysiol. Pharmacol. 5, 11–20.
Hengst, U., Cox, L. J., Macosko, E. Z., and Jaffrey, S. R. (2006). Functional and
selective RNA interference in developing axons and growth cones. J. Neurosci.
26, 5727–5732. doi: 10.1523/jneurosci.5229-05.2006
Hoffmann, A., Hofmann, F., Just, I., Lehnardt, S., Hanisch, U. K., Bruck, W., et al.
(2008). Inhibition of Rho-dependent pathways by Clostridium botulinum C3
protein induces a proinflammatory profile in microglia. Glia 56, 1162–1175.
doi: 10.1002/glia.20687
Ishizaki, T., Naito, M., Fujisawa, K., Maekawa, M., Watanabe, N., Saito, Y., et al.
(1997). p160ROCK, a Rho-associated coiled-coil forming protein kinase, works
downstream of Rho and induces focal adhesions. FEBS Lett. 404, 118–124.
doi: 10.1016/s0014-5793(97)00107-5
Jalink, K., van Corven, E. J., Hengeveld, T., Morii, N., Narumiya, S., and Moolenaar,
W. H. (1994). Inhibition of lysophosphatidate- and thrombin-induced neurite
retraction and neuronal cell rounding by ADP ribosylation of the small GTP-
binding protein Rho. J. Cell Biol. 126, 801–810. doi: 10.1083/jcb.126.3.801
Julien, S., Schnichels, S., Teng, H., Tassew, N., Henke-Fahle, S., Mueller, B. K., et al.
(2008). Purkinje cell survival in organotypic cultures: implication of Rho and
its downstream effector ROCK. J. Neurosci. Res. 86, 531–536. doi: 10.1002/jnr.
21511
Just, I., Rohrbeck, A., Huelsenbeck, S. C., and Hoeltje, M. (2011). Therapeutic
effects of Clostridium botulinum C3 exoenzyme. Naunyn Schmiedebergs Arch.
Pharmacol. 383, 247–252. doi: 10.1007/s00210-010-0589-3
Katoh, H., Aoki, J., Ichikawa, A., and Negishi, M. (1998). p160 RhoA-binding kinase
ROKalpha induces neurite retraction. J. Biol. Chem. 273, 2489–2492. doi: 10.
1074/jbc.273.5.2489
Kobayashi, K., Takahashi, M., Matsushita, N., Miyazaki, J., Koike, M., Yaginuma, H.,
et al. (2004). Survival of developing motor neurons mediated by Rho GTPase
signaling pathway through Rho-kinase. J. Neurosci. 24, 3480–3488. doi: 10.
1523/jneurosci.0295-04.2004
Koch, J. C., Barski, E., Lingor, P., Bahr, M., and Michel, U. (2011a). Plasmids
containing NRSE/RE1 sites enhance neurite outgrowth of retinal ganglion cells
via sequestration of REST independent of NRSE dsRNA expression. FEBS J. 278,
3472–3483. doi: 10.1111/j.1742-4658.2011.08269.x
Koch, J. C., Knöferle, J., Tönges, L., Michel, U., Bähr, M., and Lingor, P. (2011b).
Imaging of rat optic nerve axons in vivo. Nat. Protoc. 6, 1887–1896. doi: 10.
1038/nprot.2011.403
Koch, J. C., Solis, G. P., Bodrikov, V., Michel, U., Haralampieva, D., Shypitsyna, A.,
et al. (2013). Upregulation of reggie-1/flotillin-2 promotes axon regeneration in
the rat optic nerve in vivo and neurite growth in vitro. Neurobiol. Dis. 51, 168–
176. doi: 10.1016/j.nbd.2012.11.007
Koch, J. C., Tönges, L., Barski, E., Michel, U., Bähr, M., and Lingor, P. (2014).
ROCK2 is a major regulator of axonal degeneration, neuronal death and
axonal regeneration in the CNS. Cell Death Dis. 5:e1225. doi: 10.1038/cddis.
2014.191
Lehmann, M., Fournier, A., Selles-Navarro, I., Dergham, P., Sebok, A., Leclerc,
N., et al. (1999). Inactivation of Rho signaling pathway promotes CNS axon
regeneration. J. Neurosci. 19, 7537–7547.
Lin, X., Ogiya, M., Takahara, M., Yamaguchi, W., Furuyama, T., Tanaka, H., et al.
(2007). Sema4D-plexin-B1 implicated in regulation of dendritic spine density
through RhoA/ROCK pathway. Neurosci. Lett. 428, 1–6. doi: 10.1016/j.neulet.
2007.09.045
Lingor, P., Unsicker, K., and Krieglstein, K. (1999). Midbrain dopaminergic
neurons are protected from radical induced damage by GDF-5 application.
Short communication. J. Neural Transm. 106, 139–144. doi: 10.1007/s0070200
50146
Luo, L. (2000). Rho GTPases in neuronal morphogenesis. Nat. Rev. Neurosci. 1,
173–180. doi: 10.1038/35044547
Mackay, D. J., Nobes, C. D., and Hall, A. (1995). The Rho’s progress: a potential
role during neuritogenesis for the Rho family of GTPases. Trends Neurosci. 18,
496–501. doi: 10.1016/0166-2236(95)92773-j
Malik, I., Garrido, M., Bahr, M., Kugler, S., and Michel, U. (2006). Comparison
of test systems for RNAinterference. Biochem. Biophys. Res. Commun. 341, 245–
253. doi: 10.1016/j.bbrc.2005.12.173
Meijering, E., Jacob, M., Sarria, J. C., Steiner, P., Hirling, H., and Unser, M.
(2004). Design and validation of a tool for neurite tracing and analysis in
fluorescence microscopy images. Cytometry A 58, 167–176. doi: 10.1002/cyto.a.
20022
Michel, U., Malik, I., Ebert, S., Bahr, M., and Kugler, S. (2005). Long-term in
vivo and in vitro AAV-2-mediated RNA interference in rat retinal ganglion cells
and cultured primary neurons. Biochem. Biophys. Res. Commun. 326, 307–312.
doi: 10.1016/j.bbrc.2004.11.029
Mills, J. C., Stone, N. L., Erhardt, J., and Pittman, R. N. (1998). Apoptotic
membrane blebbing is regulated by myosin light chain phosphorylation. J. Cell
Biol. 140, 627–636. doi: 10.1083/jcb.140.3.627
Monnier, P. P., Sierra, A., Schwab, J. M., Henke-Fahle, S., and Mueller, B. K. (2003).
The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated
with the chondroitin sulfate proteoglycans of the CNS glial scar. Mol. Cell.
Neurosci. 22, 319–330. doi: 10.1016/s1044-7431(02)00035-0
Moreau-Fauvarque, C., Kumanogoh, A., Camand, E., Jaillard, C., Barbin, G.,
Boquet, I., et al. (2003). The transmembrane semaphorin Sema4D/CD100, an
inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated
after CNS lesion. J. Neurosci. 23, 9229–9239.
Mueller, B. K., Mack, H., and Teusch, N. (2005). Rho kinase, a promising drug
target for neurological disorders. Nat. Rev. Drug Discov. 4, 387–398. doi: 10.
1038/nrd1719
Neisch, A. L., Speck, O., Stronach, B., and Fehon, R. G. (2010). Rho1 regulates
apoptosis via activation of the JNK signaling pathway at the plasma membrane.
J. Cell Biol. 189, 311–323. doi: 10.1083/jcb.200912010
Niederöst, B. P., Zimmermann, D. R., Schwab, M. E., and Bandtlow, C. E. (1999).
Bovine CNS myelin contains neurite growth-inhibitory activity associated with
chondroitin sulfate proteoglycans. J. Neurosci. 19, 8979–8989.
Otsuka, S., Adamson, C., Sankar, V., Gibbs, K. M., Kane-Goldsmith, N., Ayer, J.,
et al. (2011). Delayed intrathecal delivery of RhoA siRNA to the contused spinal
cord inhibits allodynia, preserves white matter and increases serotonergic fiber
growth. J. Neurotrauma 28, 1063–1076. doi: 10.1089/neu.2010.1568
Rubin, E. J., Gill, D. M., Boquet, P., and Popoff, M. R. (1988). Functional modifi-
cation of a 21-kilodalton G protein when ADP-ribosylated by exoenzyme C3 of
Clostridium botulinum. Mol. Cell. Biol. 8, 418–426.
Sanno, H., Shen, X., Kuru, N., Bormuth, I., Bobsin, K., Gardner, H. A., et al.
(2010). Control of postnatal apoptosis in the neocortex by RhoA-subfamily
GTPases determines neuronal density. J. Neurosci. 30, 4221–4231. doi: 10.
1523/JNEUROSCI.3318-09.2010
Schaden, H., Stuermer, C. A., and Bahr, M. (1994). GAP-43 immunoreactivity and
axon regeneration in retinal ganglion cells of the rat. J. Neurobiol. 25, 1570–1578.
doi: 10.1002/neu.480251209
Semenova, M. M., Maki-Hokkonen, A. M., Cao, J., Komarovski, V., Forsberg, K. M.,
Koistinaho, M., et al. (2007). Rho mediates calcium-dependent activation of
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 273 | 9
Koch et al. RhoA-shRNA improves survival and regeneration
p38alpha and subsequent excitotoxic cell death. Nat. Neurosci. 10, 436–443.
doi: 10.1038/nn1869
Shamah, S. M., Lin, M. Z., Goldberg, J. L., Estrach, S., Sahin, M., Hu, L., et al.
(2001). EphA receptors regulate growth cone dynamics through the novel gua-
nine nucleotide exchange factor ephexin. Cell 105, 233–244. doi: 10.1016/s0092-
8674(01)00314-2
Tigyi, G., Fischer, D. J., Sebok, A., Marshall, F., Dyer, D. L., and Miledi, R.
(1996). Lysophosphatidic acid-induced neurite retraction in PC12 cells: neurite-
protective effects of cyclic AMP signaling. J. Neurochem. 66, 549–558. doi: 10.
1046/j.1471-4159.1996.66020549.x
Tönges, L., Frank, T., Tatenhorst, L., Saal, K. A., Koch, J. C., Szegö, E. M., et al.
(2012). Inhibition of rho kinase enhances survival of dopaminergic neurons and
attenuates axonal loss in a mouse model of Parkinson’s disease. Brain 135, 3355–
3370. doi: 10.1093/brain/aws254
Tönges, L., Koch, J. C., Bähr, M., and Lingor, P. (2011a). ROCKing regeneration:
Rho kinase inhibition as molecular target for neurorestoration. Front. Mol.
Neurosci. 4:39. doi: 10.3389/fnmol.2011.00039
Tönges, L., Planchamp, V., Koch, J. C., Herdegen, T., Bähr, M., and Lingor, P.
(2011b). JNK isoforms differentially regulate neurite growth and regeneration
in dopaminergic neurons in vitro. J. Mol. Neurosci. 45, 284–293. doi: 10.
1007/s12031-011-9519-1
Udagawa, T., and McIntyre, B. W. (1996). ADP-ribosylation of the G protein Rho
inhibits integrin regulation of tumor cell growth. J. Biol. Chem. 271, 12542–
12548. doi: 10.1074/jbc.271.21.12542
Wahl, S., Barth, H., Ciossek, T., Aktories, K., and Mueller, B. K. (2000). Ephrin-A5
induces collapse of growth cones by activating Rho and Rho kinase. J. Cell Biol.
149, 263–270. doi: 10.1083/jcb.149.2.263
Wang, Y. H., Wang, Y., Wang, D. W., Wu, N., Liu, D. N., and Yin, Z. Q. (2007).
Distribution and expression of RhoA in rat retina after optic nerve injury.
Ophthalmic Res. 39, 174–178. doi: 10.1159/000103237
Watanabe, N., Madaule, P., Reid, T., Ishizaki, T., Watanabe, G., Kakizuka, A., et al.
(1997). p140mDia, a mammalian homolog of Drosophila diaphanous, is a target
protein for Rho small GTPase and is a ligand for profilin. EMBO J. 16, 3044–
3056. doi: 10.1093/emboj/16.11.3044
Zhang, Y., Gu, X., and Yuan, X. (2007). Phenylalanine activates the mitochondria-
mediated apoptosis through the RhoA/Rho-associated kinase pathway in cor-
tical neurons. Eur. J. Neurosci. 25, 1341–1348. doi: 10.1111/j.1460-9568.2007.
05404.x
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 21 July 2014; accepted: 20 August 2014; published online: 05 September 2014.
Citation: Koch JC, Tönges L, Michel U, Bähr M and Lingor P (2014) Viral vector-
mediated downregulation of RhoA increases survival and axonal regeneration of
retinal ganglion cells. Front. Cell. Neurosci. 8:273. doi: 10.3389/fncel.2014.00273
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Copyright © 2014 Koch, Tönges, Michel, Bähr and Lingor. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Cellular Neuroscience www.frontiersin.org September 2014 | Volume 8 | Article 273 | 10
